https://pipelinereview.com/ULTOMIRIS-ravulizumab-cwvz-Met-Primary-Endpoint-in-CHAMPION-NMOSD-Phase-III-Trial-in-Adults-with-Neuromyelitis-Optica-Spectrum-Disorder/